Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
M. Terranova-barberio, N. Pawlowska, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma
A. Rezapour, D. Rydbeck, et al.
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
F. Ye, S. Dewanjee, et al.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
J. Cortés, S. A. Hurvitz, et al.
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
A. J. Wisdom, Y. M. Mowery, et al.
